Showing results (431-440 of 1,835) with videos related to

Sort By:
Pageof 184
ESMO Open|September 11, 2026
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohortS Wang, Q Zhang, Z Jiang, et al.
ESMO Open|September 14, 2026
Tumor genomic landscape of older patients with metastatic breast cancer☆H Gupta, K D Brantley, T Grinda, et al.
ESMO Open|June 10, 2022
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysisT Yoshino, E Van Cutsem, J Li, et al.
ESMO Open|June 10, 2022
Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?X Hou, M-Z Yang, J-B Li, et al.
ESMO Open|June 13, 2022
Role of molecular genetics in the clinical management of cholangiocarcinomaN Normanno, E Martinelli, D Melisi, et al.
ESMO Open|April 10, 2019
Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialistsAtsuko Kitano, Chikako Shimizu, Hideko Yamauchi, et al.
ESMO Open|April 10, 2019
Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancerRobert D Morgan, Sofia Stamatopoulou, Nerissa Mescallado, et al.
ESMO Open|June 25, 2019
Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumabG Mountzios, Vassiliki Kotoula, Georgia-Angeliki Kolliou, et al.
ESMO Open|June 25, 2019
How I treat metastatic triple-negative breast cancerRafael Caparica, Matteo Lambertini, Evandro de Azambuja
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Pageof 184